The first gene therapy clinical trial for LHON evaluated the safety, efficacy, and sustainability of rAAV2-ND4 IVT injections in 9 patients with ND4 gene mutations (NCT01267422) [78]. Here, MT-ND4 is linked to Leber hereditary optic neuropathy.